
Table of Contents

Preface	xvii
About the Editors.	xxi
1. Epidemiology of Platelet Transfusion	1
<i>Joseph D. Sweeney, MD, FACP, FRCPath, and Miguel Lozano, MD, PhD</i>	
How Many Platelets Are Transfused?	2
Who Are the Recipients of Platelet Transfusion?	8
Conclusions	11
References	11
2. Platelet Storage Lesions and Metabolism—Are Apoptotic and Necrotic Processes Involved?	15
<i>Stein Holme, PhD</i>	
Background	16
Necrosis vs Apoptosis Signaling Pathways During Platelet In-Vitro Storage Under Suboptimal Conditions	24
Pathogen Reduction Treatment Systems, Platelet Storage Lesions, and Apoptosis	32
The Role of Apoptosis and/or Necrosis in Platelet Lesions Occurring Under Current Optimal Storage Conditions	34
Role of Platelet Activation During Storage Under Current Optimal Conditions	38
Summary	42
References	43

3. The Manufacture of Platelet Products	53
<i>Dana V. Devine, PhD, and Katherine Serrano, PhD</i>	
Historical Overview	55
Method Description	57
Technology Development	65
Quality Assurance	67
Postproduction Modification	68
Inventory Management	68
The Future	69
References	70
4. Platelet Additive Solutions	75
<i>Pieter F. van der Meer, PhD, and Dirk de Korte, PhD</i>	
History and Rationale	76
Processing of Platelet Concentrates in PAS	78
The Composition of PASs	83
Recovery and Survival of Platelet Concentrates in PAS	97
Clinical Data	101
The Future of PASs	109
References	111
5. Pathogen Inactivation of Platelets	119
<i>Jean-Pierre Cazenave, MD, PhD; Hervé Isola; and Daniel Kientz, MD</i>	
Historical Background	119
Overview of Current Technologies for Platelet Concentrates	123
Clinical Experience	143
Introduction, or Not, of Pathogen Inactivation	160
Summary	166
References	167
6. In-Vivo and In-Vitro Evaluation of Stored Platelet Products	177
<i>Wm. Andrew Heaton, MD</i>	
In-Vivo Platelet Kinetic Measures and Radioisotope Analysis Principles	179

In-Vitro Platelet Functional Storage-Induced Effects	189
In-Vitro Platelet Functional Measures and In-Vivo Correlations	192
Biologic Evaluation of Posttransfusion Platelet Function	206
Summary	217
References	219
7. Platelet Transfusion: Prophylaxis for Spontaneous Bleeding	229
<i>Lirong Qu, MD, PhD, and Darrell J. Triulzi, MD</i>	
In the Beginning: The Origin of the 20,000/ μ L Threshold	230
Defining a Platelet Count Threshold for Spontaneous Bleeding	231
The 10,000/ μ L Threshold for Platelet Transfusion	232
Prophylactic vs Therapeutic-Only Platelet Transfusion Strategies	235
Summary	236
References	237
8. Prophylaxis of Provoked Bleeding	239
<i>Paolo Rebulli, MD</i>	
Conditions and Procedures	240
Conclusions	264
References	265
9. Platelet Transfusions for the Actively Bleeding Patient	271
<i>Lise J. Estcourt, MA, MB BChir, MA(MEL), MRCP, FRCPath; Nicola S. Curry, BA, MB BChir, MRCP, FRCPath; Gemma N. Simons, BMBS, BSc; Vipul Jairath, BSc, MBChB, MRCP; Caroline Butler; Paul Harrison, BSc, PhD, FRCPath; Simon J. Stanworth, DPhil, MRCP, FRCPath; and Michael F. Murphy, MD, FRCP, FRCPath</i>	
Clinical Assessment of Bleeding	275
Major Hemorrhage	275

Coagulopathy Associated With Major Hemorrhage	276
Laboratory Methods to Diagnose or Monitor the Actively Bleeding Patient	276
Considerations for Specific Clinical Scenarios	280
Conclusions and Future Research	306
References	307

10. Management of the Platelet-Transfusion-Refractory Patient 321

Ralph Vassallo, MD, FACP, and Mark Fung, MD, PhD

Defining Inappropriately Low Counts: Expected Increments After Platelet Transfusion	322
Seeking the Cause of Poor Adjusted Increments and Refractoriness	324
Incidence and Significance of Platelet Transfusion Refractoriness	327
Etiology of Iso- and Alloimmune Platelet Transfusion Refractoriness	329
Who Is at Particular Risk for HLA and HPA Alloimmunization? Is There a Role for Antibody Screening?	333
Do HLA- and/or HPA-Matched Units Reduce Hemorrhage or Mortality?	334
Once Alloimmune Refractoriness Occurs, What Methods Are Available for Providing Matched Platelets?	334
Which HLA-Matching Schema Yields the Highest Count Increments in Transfusion-Refractory Patients?	344
What Is the Role of HPA Matching in Transfusion- Refractory Patients?	348
Management of Highly Alloimmunized Patients for Whom No Matched Products Are Readily Available	349
Miscellaneous Matching Considerations	350
Conclusion	352
References	353

11. Platelet Transfusion in Neonates and Children . . .	359
<i>Ronald G. Strauss, MD</i>	
Platelet Transfusions in Neonates and Infants	360
Platelet Transfusions in Older Children	366
References	368
12. Dosing Considerations for Platelet Transfusion . . .	371
<i>Tina Ipe, MD, MPH; Deborah Sesok-Pizzini, MD, MBA; and Jay H. Herman, MD, FCAP</i>	
Historical Perspective on Platelet Dosing	372
Platelet Products Available for Transfusions	374
Platelet Transfusion Indications	376
Therapeutic vs Prophylactic Platelet Transfusions	378
Optimal Platelet Dose Considerations	381
Conclusions and Recommendations	394
References	394
13. ABO and RhD Groups in Platelet Transfusion	399
<i>Joan Cid, MD, PhD, and Miguel Lozano, MD, PhD</i>	
ABO Group and Platelet Transfusion	400
How ABO Incompatibility Affects Platelet Transfusion	402
Rh Group and Platelet Transfusion	409
Conclusions	418
References	419
14. Platelet Concentrates: Apheresis Platelets or Whole-Blood-Derived Pools?	427
<i>Hubert Schrezenmeier, MD, and Erhard Selfried, MD</i>	
Donor Selection and Frequency of Donations	428
Preparation of Platelet Concentrates from Apheresis or Whole Blood	431
In-Vitro Comparison of Pooled Whole-Blood-Derived Platelet Concentrates and Apheresis Platelet Concentrates	435
In-Vivo Recovery of Radiolabeled Platelet Concentrates	437

Posttransfusion Platelet Increment and Clinical Bleeding After Transfusion of Pooled Platelet Concentrates and Apheresis Platelet Concentrates	438
Febrile Nonhemolytic Transfusion Reactions	441
Bacterial and Viral Contamination	442
Alloimmunization and Platelet Refractoriness	448
Transfusion-Related Acute Lung Injury	448
Donor Perspective	450
Conclusion	455
References	455
15. In-Vivo Evaluation of Platelet Transfusion	
Efficacy	471
<i>Tor Hervig, MD, and Torunn Oveland Apelseth, MD</i>	
In-Vivo Evaluation of Platelet Viability	472
In-Vivo Evaluation of Platelet Functionality	479
Conclusion	486
References	486
16. Allergic Transfusion reactions	493
<i>William J. Savage, MD, PhD; Aaron A. R. Tobian, MD, PhD; and Paul M. Ness, MD</i>	
Clinical Manifestations	494
Pathophysiology	495
Diagnosis	498
Premedication	499
Practical Approach to the Management of ATRs	499
Summary	502
References	502
17. TRALI and Other Nonallergic Reactions to Platelet Transfusion	507
<i>Jay S. Ravai, MD, and Mark H. Yazer, MD</i>	
Transfusion-Related Acute Lung Injury	507
Transfusion-Associated Circulatory Overload	516
Febrile Nonhemolytic Transfusion Reactions	519
References	530

18. Bacterial Contamination of Platelet Products 541

*Richard J. Benjamin, MD, PhD, and Anne F. Eder, MD,
PhD*

Sources and Nature of Bacterial Contamination.	544
Investigating Blood Donors Associated With Contaminated Platelet Components	546
Current Estimates of Sepsis and Contamination Risk.	548
Determinants of Contamination Risk	550
Mechanism of Missed Detection by Early Culture Techniques	555
Bacterial Contamination of Platelets and Evidence of Clinical Outcome.	556
Point-of-Issue Testing for Bacteria.	557
Modalities To Further Reduce Bacterial Risk	558
Conclusions.	562
References.	562

19. Avoiding Platelet Transfusions 567

*Miguel Lozano, MD, PhD, and Joseph D. Sweeney, MD,
FACP, FRCPath*

General Measures	568
Red Blood Cell Transfusion	568
Hemostatic Drugs	570
Platelet Substitutes	577
Thrombopoietic Agents	578
Conclusions.	583
References.	583

Index. 591